The DOI matches its Crossref record; the references it cites are not checked yet.
Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture
Abstract
The aim of this study was to examine the effects of risedronate (5 mg/daily) in patients identified solely on the basis of a prior fragility fracture, without BMD as an inclusion criterion. A total of 1,802 patients were examined from the VERT-NA and VERT-MN clinical trials. Lateral radiographs (T4 to L4) were obtained at baseline and annually; incident fractures were evaluated using quantitative and semiquantitative methods at the central facility. BMD was measured at the lumbar spine and femoral neck by dual-energy X-ray absorptiometry. Secondary analyses evaluated vertebral fracture efficacy in patient subgroups categorized according to the presence of risk factors for osteoporosis at baseline (age, femoral neck BMD, lumbar spine BMD, more severe BMD, height, weight, body mass index, prevalent nonvertebral fracture status, smoking, and bone turnover marker levels). Over 3 years, risedronate reduced the risk of new vertebral fractures by 44% (95% CI, 28% to 56%) compared with placebo. In patients subgrouped according to the presence or absence of putative risk factors, the efficacy of risedronate was comparable across all groups (all treatment-by-non BMD subgroup interactions p > or =0.210). Adjustment for age, baseline BMD, and prevalent vertebral fractures on fracture risk gave results similar to the unadjusted analysis. In patients taking placebo, the incidence of new vertebral fracture was higher in several of the high-risk categories (elderly, T-score < or = -2.5 SD).…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is true for fracture patients with BMD in both the low bone mass and osteoporosis range [49–58].”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [53]
In the citing paper
“There are abundant data that patients with spine and hip fractures will have reduced fracture risk if treated with pharmacologic therapy.”
From Clinician’s Guide to Prevention and Treatment of Osteoporosis (2014) · cites this paper as [53]
Citations
The citation lists are queued
They are fetched later and appear here then.
References 40 · Cited by 108
Metadata
- Authors
- Kanis, J. A., Barton, I. P., & Johnell, O.
- Affiliations
- University of Sheffield (GB)
- Procter & Gamble (United Kingdom) (GB)
- Corresponding author
- Kanis, J. A.
- Venue
- Osteoporosis International
- Published
- 2004-07-23
- Volume
- 16
- Issue
- 5
- Pages
- 475-482
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W2012044560
- Cited by
- 108
- References
- 40
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 8 · 2022: 2 · 2021: 1 · 2020: 3 · 2019: 1 · 2018: 4 · 2017: 5 · 2016: 4 · 2015: 6 · 2014: 3 · 2013: 6 · 2012: 5
- FWCI
- 7.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- risedronate, vertebral fractures, fragility fractures, osteoporosis, bisphosphonates, fracture risk reduction, bone mineral density, subgroup analysis
- MeSH terms
- Risedronic Acid, Aged, Anthropometry, Double-Blind Method, Female, Femur Neck, Humans, Lumbar Vertebrae, Middle Aged, Recurrence, Risk Factors, Etidronic Acid, Absorptiometry, Photon, Bone Density, Osteoporosis, Postmenopausal, Spinal Fractures
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. https://app.cochat.ai/papers/10.1007/s00198-004-1698-y
- The paper
- Kanis, J. A., Barton, I. P., & Johnell, O. (2005). Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. Osteoporosis International. https://doi.org/10.1007/s00198-004-1698-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.